Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

20141,490 citationsJournal Articlebronze Open Access

Authors

Valentin Goede · Integrated Oncology (United States)

Kirsten Fischer · University Hospital Cologne

Raymonde Busch

Anja Engelke · University Hospital Cologne

Barbara Eichhorst · Integrated Oncology (United States)

Clemens‐Martin Wendtner · München Klinik Schwabing

Tatiana Chagorova

Javier de la Serna

Abstract

Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions. In this patient population, obinutuzumab was superior to rituximab when each was combined with chlorambucil. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT01010061.).

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Immunodeficiency and Autoimmune Disorders

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 12, pp. 1101-1110

DOI: 10.1056/nejmoa1313984

Field-Weighted Citation Impact: 108.38